Table 2 Baseline characteristics of our study population stratified by glycaemic status according to HbA1c results (ADA criteria)
Characteristic | Available data | NGT | Prediabetes | Diabetes | p-value | Known diabetes |
|---|---|---|---|---|---|---|
Study population—no known diabetes, n = 841 | 320 (38.1%) | 461 (54.8%) | 60 (7.1%) | 433 | ||
Age—yr [median (IQR)] | 841/841 | 63 (56–70) | 66 (59–71) | 66 (57–72) | 0.026 | 68 (61–75) |
Gender (male) | 841/841 | 242 (75.6%) | 334 (72.5%) | 44 (73.3%) | 0.610 | 314 (72.5%) |
Body-mass index [median (IQR)] | 796/841 | 26 (24–29) | 27 (25–30) | 29 (25–32) | < 0.001 | 28 (26–32) |
Smokers | 801/841 | 103 (33.1%) | 169 (39.1%) | 26 (44.8%) | 0.035 | 84 (21.9%) |
Snuff users | 560/841 | 11 (4.9%) | 26 (8.9%) | 0 (0%) | 0.034 | 9 (3.5%) |
eGFR (mL/min/1.73 m2)—MDRD equation [median (IQR)] | 769/841 | 85 (71–96) | 81 (71–94) | 85 (76–98) | 0.104 | 73 (55–92) |
Medical history | ||||||
Previous myocardial infarction | 841/841 | 82 (25.6%) | 108 (23.4%) | 14 (23.3%) | 0.769 | 103 (23.8%) |
Hypertension | 841/841 | 72 (22.5%) | 110 (23.9%) | 13 (21.7%) | 0.869 | 179 (41.3%) |
Heart failure | 841/841 | 3 (0.9%) | 7 (1.5%) | 1 (1.7%) | 0.756 | 14 (3.2%) |
Atrial fibrillation | 841/841 | 10 (3.1%) | 21 (4.6%) | 4 (6.7%) | 0.371 | 26 (6.0%) |
Previous PCI or CABG | 841/841 | 64 (20.0%) | 99 (21.5%) | 11 (18.3%) | 0.791 | 83 (19.2%) |
Stroke | 841/841 | 7 (2.2%) | 17 (3.7%) | 1 (1.7%) | 0.395 | 23 (5.3%) |
Peripheral artery disease | 841/841 | 3 (0.9%) | 6 (1.3%) | 2 (3.3%) | 0.325 | 13 (3.0%) |
Chronic kidney disease | 841/841 | 2 (0.6%) | 4 (0.9%) | 0 (0%) | 0.733 | 14 (3.2%) |
Chronic obstructive pulmonary disease | 841/841 | 2 (0.6%) | 6 (1.3%) | 1 (1.7%) | 0.596 | 8 (1.8%) |
Medications on discharge | ||||||
Aspirin | 841/841 | 271 (84.7%) | 391 (84.8%) | 47 (78.3%) | 0.418 | 280 (64.7%) |
Clopidogrel | 841/841 | 175 (54.7%) | 282 (61.2%) | 35 (58.3%) | 0.195 | 190 (43.9%) |
Ticagrelor | 841/841 | 92 (28.8%) | 82 (17.8%) | 11 (18.3%) | 0.001 | 56 (12.9%) |
Prasugrel | 841/841 | 2 (0.6%) | 5 (1.1%) | 0 (0%) | 0.599 | 8 (1.9%) |
ACE-inhibitors | 841/841 | 218 (68.1%) | 278 (60.3%) | 39 (65.0%) | 0.08 | 202 (46.7%) |
ARB | 841/841 | 44 (13.8%) | 96 (20.8%) | 4 (6.7%) | 0.003 | 95 (21.9%) |
Beta-receptor blockers | 841/841 | 278 (86.9%) | 394 (85.5%) | 46 (76.7%) | 0.121 | 277 (64.0%) |
Statins | 841/841 | 276 (86.3%) | 393 (85.3%) | 47 (78.3%) | 0.285 | 271 (62.6%) |
Dihydropyridines | 841/841 | 60 (18.8%) | 88 (19.1%) | 13 (21.7%) | 0.870 | 111 (25.6%) |
Diuretics | 841/841 | 49 (15.3%) | 80 (17.4%) | 10 (16.7%) | 0.752 | 101 (23.3%) |
Warfarin | 841/841 | 11 (3.4%) | 26 (5.6%) | 5 (8.3%) | 0.178 | 29 (6.7%) |